共 200 条
[31]
Sadelain M(2015)A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1 Cancer Res 75 3800-51
[32]
Topalian SL(2015)PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 372 2509-319
[33]
Hodi FS(2014)Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type Cancer Epidemiol Biomark Prev. 23 2965-1437
[34]
Brahmer JR(2015)The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints Cancer Discov. 5 43-330
[35]
Gettinger SN(2015)PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 372 311-144
[36]
Smith DC(2015)Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial J Clin Oncol 33 1430-2012
[37]
McDermott DF(2015)Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 320-undefined
[38]
Brahmer JR(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-undefined
[39]
Tykodi SS(2015)Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer J Clin Oncol 33 2004-undefined
[40]
Chow LQ(undefined)undefined undefined undefined undefined-undefined